Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
41
BCYC Quote, Financials, Valuation and Earnings
Last price:
$6.68
Seasonality move
:
-2.13%
Day range:
$6.73 - $7.13
52-week range:
$6.03 - $15.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.31x
P/B ratio:
1.10x
Volume:
232.7K
Avg. volume:
270.9K
1-year change:
-49.43%
Market cap:
$491.1M
Revenue:
$35.3M
EPS (TTM):
-$3.63
Analysts' Opinion
-
Consensus RatingBicycle Therapeutics Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.50, Bicycle Therapeutics Plc has an estimated upside of 203.67% from its current price of $7.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $7.08.
Fair Value
-
According to the consensus of 10 analysts, Bicycle Therapeutics Plc has 203.67% upside to fair value with a price target of $21.50 per share.
BCYC vs. S&P 500
-
Over the past 5 trading days, Bicycle Therapeutics Plc has overperformed the S&P 500 by 3.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bicycle Therapeutics Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bicycle Therapeutics Plc has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bicycle Therapeutics Plc reported revenues of $11.7M.
Earnings Growth
-
Bicycle Therapeutics Plc earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bicycle Therapeutics Plc reported earnings per share of -$0.85.
Enterprise value:
-150.7M
EV / Invested capital:
--
Price / LTM sales:
17.31x
EV / EBIT:
--
EV / Revenue:
-5.32x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
0.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$21.5M
Return On Assets:
-28.31%
Net Income Margin (TTM):
-886.68%
Return On Equity:
-34.37%
Return On Invested Capital:
-33.96%
Operating Margin:
-624.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $24.9M | $37M | $28.3M | $2.7M | $11.7M | |
| Gross Profit | $18.6M | $29.8M | $21.5M | $509.2K | $9.9M | |
| Operating Income | -$193.6M | -$235M | -$330.9M | -$72.8M | -$72.9M | |
| EBITDA | -$187.3M | -$227.8M | -$324.1M | -$70.6M | -$71.1M | |
| Diluted EPS | -$5.00 | -$3.30 | -$3.63 | -$0.74 | -$0.85 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $272.9M | $381.3M | $603M | $966.2M | $738.8M | |
| Total Assets | $281.3M | $417.1M | $638.7M | $996.7M | $764M | |
| Current Liabilities | $30.2M | $41.6M | $69.7M | $56.4M | $69.3M | |
| Total Liabilities | $110.5M | $127.7M | $222.7M | $165.7M | $145.5M | |
| Total Equity | $170.8M | $289.5M | $416M | $831M | $618.5M | |
| Total Debt | $33.1M | $41.2M | $41M | $5.7M | $1.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$45.7M | -$203.5M | -$239.9M | -$40.5M | -$70.6M | |
| Cash From Investing | -$4.5M | -$920.5K | -$2.1M | -$438.8K | -$670.9K | |
| Cash From Financing | $258.1M | $522.1M | -$2M | -$29.8M | -$29.7K | |
| Free Cash Flow | -$50.2M | -$204.4M | -$242.1M | -$40.9M | -$71.3M | |
BCYC
Sector
Market Cap
$491.1M
$28.1M
Price % of 52-Week High
45.77%
50%
Dividend Yield
0%
0%
Shareholder Yield
1.72%
-1.54%
1-Year Price Total Return
-49.43%
-17.67%
Beta (5-Year)
1.524
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.91
200-day SMA
Sell
Level
$7.72
Bollinger Bands (100)
Sell
Level
6.7 - 7.92
Chaikin Money Flow
Sell
Level
-16.4M
20-day SMA
Sell
Level
$7.10
Relative Strength Index (RSI14)
Buy
Level
50.89
ADX Line
Buy
Level
14.92
Williams %R
Neutral
Level
-61.9524
50-day SMA
Sell
Level
$7.14
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
9.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7918)
Sell
CA Score
(Annual)
Level (-0.7672)
Buy
Beneish M-Score
(Annual)
Level (-2.9066)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (0.3153)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Stock Forecast FAQ
In the current month, BCYC has received 6 Buy ratings 4 Hold ratings, and 0 Sell ratings. The BCYC average analyst price target in the past 3 months is $21.50.
-
Where Will Bicycle Therapeutics Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bicycle Therapeutics Plc share price will rise to $21.50 per share over the next 12 months.
-
What Do Analysts Say About Bicycle Therapeutics Plc?
Analysts are divided on their view about Bicycle Therapeutics Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bicycle Therapeutics Plc is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Bicycle Therapeutics Plc's Price Target?
The price target for Bicycle Therapeutics Plc over the next 1-year time period is forecast to be $21.50 according to 10 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is BCYC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bicycle Therapeutics Plc is a Buy. 6 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BCYC?
You can purchase shares of Bicycle Therapeutics Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bicycle Therapeutics Plc shares.
-
What Is The Bicycle Therapeutics Plc Share Price Today?
Bicycle Therapeutics Plc was last trading at $6.68 per share. This represents the most recent stock quote for Bicycle Therapeutics Plc. Yesterday, Bicycle Therapeutics Plc closed at $7.08 per share.
-
How To Buy Bicycle Therapeutics Plc Stock Online?
In order to purchase Bicycle Therapeutics Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BCYC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BCYC
Sector
P/E ratio
--
23.88x
PEG ratio
-0.20x
-0.01x
P/B ratio
1.10x
1.82x
Price / LTM sales
17.31x
1.59x
Growth Metrics
BCYC
Sector
Revenue growth
331.43%
4.73%
Earnings growth
-13.94%
11.11%
Revenue (5-year growth)
20.56%
6.46%
Earnings forecast
-$0.94
-$0.18
Profitability
BCYC
Sector
Profitability FY 2024
$28.1M
$3.6M
Return on invested capital
-33.96%
-31.77%
Return on assets
-28.31%
-28.18%
Return on equity
-34.37%
-37.47%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Jan
29
Balance Sheet
BCYC
Sector
Total cash
$648.3M
$26.3M
Short term investments
--
$26M
Total assets
$956.9M
$76.9M
Long term debt
$1.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
